- Trials with a EudraCT protocol (39,264)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39,264 result(s) found for: 1.
Displaying page 657 of 1,964.
EudraCT Number: 2012-001786-32 | Sponsor Protocol Number: IRST172.03 | Start Date*: 2012-06-19 | |||||||||||||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | |||||||||||||||||||||||
Full Title: Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic r... | |||||||||||||||||||||||
Medical condition: metastatic melanoma or renal cell carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002295-13 | Sponsor Protocol Number: APHP200552 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux Paris | |||||||||||||
Full Title: Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of conc... | |||||||||||||
Medical condition: The study population will consist of adults (18-80 years old) hospitalised for ≤48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test posit... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000344-67 | Sponsor Protocol Number: DCR-PHXC-104 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Dicerna Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hype... | |||||||||||||
Medical condition: Primary Hyperoxaluria Type 3 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004769-41 | Sponsor Protocol Number: 7572 | Start Date*: 2020-02-18 |
Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
Full Title: Prospective randomized versus placebo study evaluating the feasibility of plasma therapy in septic shock induced coagulopathy | ||
Medical condition: Septic shock | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002766-13 | Sponsor Protocol Number: 1088/12 | Start Date*: 2013-01-24 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: A phase 2 study of temozolomide in patients affected by metastatic colonrectal cancer with hypermethylation of 06-methylguanine-dna-methyltransferase | |||||||||||||
Medical condition: metastatic colonrectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002984-32 | Sponsor Protocol Number: FER-COM-16-004 | Start Date*: 2017-02-16 | |||||||||||
Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI | |||||||||||||
Full Title: Treatment of the Reynaud's Disease associated with ischemic ulcers in patients affected by sistemic sclerosis | |||||||||||||
Medical condition: SISTEMIC SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004787-20 | Sponsor Protocol Number: MED3-201601 | Start Date*: 2017-10-11 | |||||||||||
Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | |||||||||||||
Full Title: An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over ... | |||||||||||||
Medical condition: Patients with resectable advanced stage HNSCC (T1–T4 N0-N2 M0) with intermediate risk (resection margins > 5 mm, no perineural invasion and no extracapsular evasion) for whom definite RT post surge... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003949-28 | Sponsor Protocol Number: Inco_Ona1 | Start Date*: 2018-08-07 | |||||||||||
Sponsor Name:PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA | |||||||||||||
Full Title: Incobotulinumtoxin versus Onabotulinumtoxin in the treatment of patients with overactive bladder syndrome | |||||||||||||
Medical condition: neurogenic overactive bladder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004351-39 | Sponsor Protocol Number: FARM8MXYFL | Start Date*: 2011-10-28 | |||||||||||||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||||||||||||
Full Title: Phase II, randomized, double arm, multi-center study evaluating the efficacy and safety of azithromycin for the long term prophylactic treatment of COPD in primary antibody deficiency patients with... | |||||||||||||||||||||||
Medical condition: primary immunodefciency patients with COPD and frequent exacerbations | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002853-13 | Sponsor Protocol Number: EWALL-BOLD | Start Date*: 2018-03-01 | |||||||||||
Sponsor Name:Goethe Universität Frankfurt | |||||||||||||
Full Title: Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Bli... | |||||||||||||
Medical condition: Patient aged 56 and 74 with CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000580-17 | Sponsor Protocol Number: TRANSLATE-RE | Start Date*: 2016-07-13 | |||||||||||||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO | |||||||||||||||||||||||
Full Title: RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN RENAL CELL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – kidney STUDY | |||||||||||||||||||||||
Medical condition: metastatic renal cell carcinoma (mRCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005145-23 | Sponsor Protocol Number: 53736 | Start Date*: 2017-08-29 | |||||||||||||||||||||
Sponsor Name:DIPARTIMENTO DI SCIENZE CHIRURGICHE - UNIVERSITà DEGLI STUDI DI TORINO | |||||||||||||||||||||||
Full Title: Prospective randomized trial comparing corifollitropin alfa (CF-alfa) late start (day 4) vs. CF-alfa standard start (day2) in poor, normal and potential high-responders undergoing IVF/ICSI | |||||||||||||||||||||||
Medical condition: Women with low reproductive capacity | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002102-58 | Sponsor Protocol Number: TJT2012 | Start Date*: 2020-06-12 | |||||||||||
Sponsor Name:CHU de Liège | |||||||||||||
Full Title: Mesenchymal stromal cell therapy for severe COVID-19 infection | |||||||||||||
Medical condition: Patients with severe COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002585-33 | Sponsor Protocol Number: PETAL | Start Date*: 2023-01-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002513-36 | Sponsor Protocol Number: ASP-1929-301 | Start Date*: 2019-08-16 | |||||||||||
Sponsor Name:Rakuten Aspyrian, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck ... | |||||||||||||
Medical condition: Locoregional, recurrent head and neck squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003325-17 | Sponsor Protocol Number: P080403 | Start Date*: 2008-10-24 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude ARCTIC Comparaison randomisée 1/ d'un traitement antiplaquettaire ajusté par monitoring à un traitement standard à dose fixe pour stenting coronaire avec DES, et 2/ d'un arrêt versus poursuit... | |||||||||||||
Medical condition: Patients devant recevoir au moins un stent actif quel que soit le contexte | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004593-56 | Sponsor Protocol Number: CAVE-2 | Start Date*: 2022-05-19 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE | |||||||||||||
Full Title: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients | |||||||||||||
Medical condition: Pre-treated RAS/BRAF wild type metastatic colorectal cancer patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005663-31 | Sponsor Protocol Number: 12020 | Start Date*: 2022-10-04 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO DI TORINO | |||||||||||||
Full Title: CARotid plaqUe StabilizatiOn and regression with evolocumab) | |||||||||||||
Medical condition: atherosclerosis desead | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002251-42 | Sponsor Protocol Number: GZ-2016-11512. | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: An open-label, single-center study on the safety and efficacy of avalglucosidase alpha in late-onset Pompe patients ≥5 years | |||||||||||||
Medical condition: Late onset Pompe disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-006004-16 | Sponsor Protocol Number: 03PDE2020 | Start Date*: 2021-07-16 |
Sponsor Name:Celon Pharma S.A. | ||
Full Title: Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Diseas... | ||
Medical condition: Levodopa-induced dyskinesia in Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
